Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine by welcoming Mass General Cancer Center. “We are thrilled to welcome Mass General Cancer Center, one of the world’s most respected centers, to the Caris Precision Oncology Alliance,” said George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris. “We’re eager to work with their researchers and investigators on our shared mission of improving outcomes of all patients affected by cancer through precision oncology research.” Learn more: https://lnkd.in/ggni-zgg
Caris Life Sciences’ Post
More Relevant Posts
-
Take a moment to read our great blog post!!!
Be sure to check out our latest blog post on Mary Crowley Cancer Research's attendance at the American Society of Clinical Oncology (ASCO)'s Annual Meeting! View abstracts, posters, presentations and more! https://lnkd.in/gN2ddidx
To view or add a comment, sign in
-
November is #LungCancerAwarenessMonth 🫁 and at Total Health, we're committed to keeping you updated on the latest developments, in patient-friendly language. At our 2023 ‘Review and Renew’ Summer Oncology Retreat, Dr. Millie Das from Stanford University reviewed some of the critical updates in lung cancer treatment presented at this year’s meeting of the American Society for Clinical Oncology (ASCO). You can read a plain language summary of Dr. Das’ presentation here 👉 https://lnkd.in/gm4mPkgp You can learn more about lung cancer screening and treatment, in plain language, by visiting the ‘Patient Resources’ section of our website. #LungCancerAwareness #KnowledgeIsEmpowerment #OncEd #Oncology #Education #LungCancer
ASCO 2023 Napa Valley: Lung Cancer Updates with Dr Millie Das
totalhealthoncology.com
To view or add a comment, sign in
-
Our latest recommendations for NTRK fusion testing and management in lung cancer - Herbert Loong Peters Solange Alexander Drilon CUHK Medicine Erin Rudzinski #LungCancer #Cancer #OncoDaily #Oncology #NTRK #LCSM
Herbert Loong: Our latest recommendations for NTRK fusion testing and management in lung cancer - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
⭐️Today is #WorldCancerDay ! The global cancer incidence is on the rise, and the global cancer burden is expected to reach 28.4 million cases in 2040, a 47% rise from 2020. 👉🏼Globalizing precision oncology should be a major priority for cancer care in the upcoming decades. It is time to modify the precision oncology mantra: Give the right drug, to the right patient, at the right time in every country, to think globally and act locally. Read our commentary published in American Association for Cancer Research Journal Cancer Discovery Elizabeth McKenna 👉🏼Think Globally, Act Locally: Globalizing Precision Oncology OncoAlert Link: https://lnkd.in/eXXsjE-3
To view or add a comment, sign in
-
-
Important factors to evaluate the quality of oncological care in LMICs - City Cancer Challenge https://lnkd.in/gTtCqgXP #oncodaily #oncology #cancer #research #CCan
Important factors to evaluate the quality of oncological care in LMICs - City Cancer Challenge - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
What would happen if cancer patients, survivors and caregivers were given $1M to invest strategically in research to improve what they view as gaps in precision oncology in Canada? What research questions would they want addressed? What areas would the prioritize? The Terry Fox Research Institute’s Marathon of Hope Cancer Centres Network’s set out to answer these questions with the launch of a new patient-initiated research program called the Patient Voices in Research Initiative. A first-of-its-kind for precision oncology research, this program will support high-quality research that answers key themes identified by members of the MOHCCN Patient Working Group, a group of 30 cancer patients, survivors and caregivers from across Canada. 🔬 READ OUR LATEST PRESS RELEASE: New funding initiative shaped by cancer patients is first of its kind to address gaps in precision oncology ▶ https://bit.ly/461kWNB #TeamCanadaOfCancerResearch #PatientEngagement The Terry Fox Research Institute The Terry Fox Foundation
To view or add a comment, sign in
-
-
Merck's anti-TIGIT quest. Can vibostolimab and pembrolizumab outshine pembrolizumab as a monotherapy? Hard to bet on TIGIT at the moment. The pursuit of anti-TIGIT therapies, as exemplified by the ongoing trial with vibostolimab, shows promise despite previous setbacks in cancer research. The potential efficacy of vibostolimab combined with pembrolizumab, particularly in endometrial cancer, could mark a significant breakthrough, validating the broader use of anti-TIGIT approaches in oncology. By aiming to exceed the success of pembrolizumab monotherapy, Merck's trial not only seeks to enhance the market potential of vibostolimab but also holds the promise of transformative advancements in cancer treatment. For exclusive coverage on Endometrial cancer at ASCO 2024 annual meeting, visit: https://lnkd.in/gw75iYYn #AntiTIGIT #Vibostolimab #Pembrolizumab #CancerResearch #Oncology #EndometrialCancer #Merck #ClinicalTrials #CancerBreakthrough #PharmaInnovation #CancerTreatment #Immunotherapy #MedicalResearch #PharmaNews #HealthcareAdvancements
Endometrial Cancer Preview ASCO 2024
delveinsight.com
To view or add a comment, sign in
-
ASCO Plenary Series allows you the opportunity to present your data globally within 2 months of submission! - Erika Hamilton American Society of Clinical Oncology (ASCO) #Abstracts #ASCO24 #Cancer #ErikaHamilton #GlobalScope #OncoDaily #Oncology
Erika Hamilton: ASCO Plenary Series allows you the opportunity to present your data globally within 2 months of submission! - Oncodaily | Oncology News, Insights, Stories
oncodaily.com
To view or add a comment, sign in
-
This new review article is all about Tagraxofusp for BPDCN - ACS Journal Cancer Wei Ying Jen, Marina Konopleva, Naveen Pemmaraju, MD https://lnkd.in/gyAWR2Xx #oncodaily #oncology #cancer #hematologicalmalignancies #Tagraxofusp #BPDCN #AML #clinicalresearch #cancertherapy
This new review article is all about Tagraxofusp for BPDCN - ACS Journal Cancer - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
The treatment of #lungcancer has changed dramatically from decades past, when cytotoxic chemotherapy was the only option. We now have a much better understanding of the different molecular subtypes of lung cancer, and this enables the use of highly effective targeted treatments and immunotherapies, which are also significantly less toxic. November is #LungCancerAwarenessMonth🫁, and at Total Health, we're committed to keeping you updated on the latest developments, in patient-friendly language. At our 2023 West Oncology Virtual Conference for Advanced Practicioners and Nurses, Jason Porter from The West Clinic outlined some of the recent updates in treatment for lung cancer. You can read a summary of Dr. Porter’s presentation here: 👉 https://ow.ly/XbGz50QbIKv You can learn more about lung cancer screening and treatment, in plain language, by visiting the ‘Patient Resources’ section of our website. #LungCancerAwareness #KnowledgeIsEmpowerment #OncEd #Oncology #Education #LungCancer
West Oncology APP Virtual: Updates in Lung Cancer Treatment with Dr Jason Porter
totalhealthoncology.com
To view or add a comment, sign in